Longitudinal study of β2-microglobulin abnormalities in schizophrenia
| Autor: | Kurudunje Taranath Shetty, Naveen A. Reddy, Bangalore N. Gangadhar, Seetharamaiah Chittiprol, Narendran Neelakantachar, Ganesan Venkatasubramanian |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Oncology Longitudinal study Psychosis medicine.medical_specialty Neuroimmunomodulation medicine.drug_class Immunology Atypical antipsychotic medicine.disease_cause Internal medicine parasitic diseases Humans Immunology and Allergy Medicine Pharmacology Risperidone business.industry Dopamine antagonist Immune dysregulation medicine.disease Endocrinology Schizophrenia Immune System Disease Progression Female beta 2-Microglobulin business Antipsychotic Agents Follow-Up Studies Psychopathology medicine.drug |
| Zdroj: | International Immunopharmacology. 9:1215-1217 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2009.07.002 |
| Popis: | In an earlier cross-sectional study, we reported antipsychotic-naive schizophrenia patients to have significantly elevated beta2-microglobulin (beta2M) level suggestive of its potential association with the pathogenesis of schizophrenia. In this study, we present the follow-up analyses of beta2M in 31 patients from the previous study who were re-assessed after 92.1+/-7.2 days of antipsychotic treatment. Compared to baseline, there was a further significant elevation of beta2M in schizophrenia patients following treatment, especially in those who were treated with risperidone. Also, there was a significant negative correlation between beta2M level and total psychopathology score during follow-up in risperidone group. The study findings extend further support the role for beta2M in the pathogenesis of schizophrenia strengthening the case for immune dysregulation. Moreover, the observations suggest the possibility that the mechanism of action of antipsychotics might involve alteration of immune parameters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect